论文部分内容阅读
目的:探讨参麦注射液辅助治疗新生儿窒息所致心肌损害的疗效和安全性。方法:选择我院儿科2013年1月至2015年12月收治的70例新生儿窒息所致心肌损害的患儿,按照随机抽样法分为治疗组和对照组各35例,两组患儿在常规治疗的基础上,治疗组采用磷酸肌酸钠联合参麦注射液治疗,对照组采用磷酸肌酸钠治疗,观察两组患儿的临床疗效和不良反应。结果:治疗组的总有效率94.3%,明显高于对照组的80.0%(P<0.05);治疗组的LVEF、FS、CK-MB、α-HBDH和c Tn I等指标的改善明显优于对照组(P<0.05);两组不良反应比较差异无统计学意义(P>0.05)。结论:参麦注射液辅助治疗新生儿窒息所致心肌损害,可提高疗效,安全性高,值得临床推广和使用。
Objective: To investigate the efficacy and safety of Shenmai injection in the treatment of neonatal asphyxia-induced myocardial damage. Methods: Seventy children with myocardial damage induced by asphyxia of newborns admitted to our pediatric department from January 2013 to December 2015 were randomly divided into treatment group (35 cases) and control group (35 cases) On the basis of routine treatment, the treatment group was treated with sodium creatine phosphate and Shenmai injection, while the control group was treated with sodium creatine phosphate. The clinical efficacy and adverse reactions of the two groups were observed. Results: The total effective rate of the treatment group was 94.3%, which was significantly higher than that of the control group (80.0%, P <0.05). The improvement of LVEF, FS, CK-MB, α-HBDH and cTn I in the treatment group was significantly better than (P <0.05). There was no significant difference in adverse reactions between the two groups (P> 0.05). Conclusion: Shenmai injection in the treatment of myocardial damage caused by neonatal asphyxia can improve the curative effect and safety, which is worthy of clinical promotion and use.